Td cowen raised the firm Destination of the price on therapeutic crossed (Tvtx) to $ 30 from $ 24 and maintain a purchase rating on the action. The firm said that the Q4 Filspari Results were in line with the pregnoning with impressive 40% of the fourth network of network of the fourth of 37% of the fourth. Igan’s growth of Igan must continue in 2025 as there are tail multiples and fSGS SNDA will happen at the end of Q1 Setting a potential approval.
Posted before Thefly – the final source for null time in the market market. Try now >>
View Top Recommended Stocks From Analysts >>
Read more about TVTX:
https://media.zenfs.com/en/tipranks_452/bd23518bddbecaa2e26b66cd7da7f21e
2025-02-22 17:20:00
